Arlington Trust’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$196K Sell
771
-120
-13% -$28K 0.02% 118
2026
Q1
$218K Buy
891
+97
+12% +$22.6K 0.02% 92
2025
Q4
$164K Sell
794
-1,170
-60% -$231K 0.02% 104
2025
Q3
$364K Buy
1,964
+458
+30% +$78.5K 0.07% 122
2025
Q2
$230K Hold
1,506
0.04% 162
2025
Q1
$250K Sell
1,506
-1,528
-50% -$239K 0.05% 150
2024
Q4
$439K Buy
3,034
+403
+15% +$62.5K 0.09% 104
2024
Q3
$426K Sell
2,631
-71
-3% -$11.3K 0.09% 102
2024
Q2
$395K Buy
2,702
+975
+56% +$145K 0.09% 99
2024
Q1
$273K Sell
1,727
-494
-22% -$78.6K 0.07% 119
2023
Q4
$348K Sell
2,221
-16,582
-88% -$2.54M 0.1% 101
2023
Q3
$2.93M Buy
+18,803
New +$3.1M 1.2% 18

Other funds holding JNJ

Arlington Trust's JNJ Position: Q2 2026 in Review

Arlington Trust reduced its Johnson & Johnson (JNJ) stake by 13% in Q2 2026, selling an estimated $28K and leaving 771 shares worth $196K. The position accounts for 0.02% of the portfolio, ranked #118.

Arlington Trust first reported a position in JNJ in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.93M in Q3 2023. 4,678 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Arlington Trust held 771 shares of Johnson & Johnson worth $196K as of Q2 2026.
  • Arlington Trust sold 120 Johnson & Johnson shares in Q2 2026, an estimated $28K.
  • Johnson & Johnson made up 0.02% of Arlington Trust's portfolio in Q2 2026, its #118 holding.
  • Arlington Trust first reported a position in Johnson & Johnson in Q3 2023 and has held it in 12 quarters since.
  • Arlington Trust's Johnson & Johnson position peaked at $2.93M in Q3 2023.
  • 4,678 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Arlington Trust's 13F filing for Q2 2026, filed 7 Jul 2026.